ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone Side Effect Management
No Heart or Clotting Issues in Diabetic Men Using Testosterone after 3.5 years
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="Nelson Vergel" data-source="post: 36835" data-attributes="member: 3"><p><strong>Effect of Testosterone Therapy on Cardiovascular and Thrombotic Events in Hypogonad Men with T2DM</strong></p><p></p><p><strong>Program:</strong> Abstracts - Orals, Poster Previews, and Posters</p><p><strong>Session:</strong> SAT 134-160-Male Reproductive Endocrinology and Male Reproductive Tract (posters)</p><p>Bench to Bedside</p><p></p><p><strong>ENDO 2016 Meeting. Saturday, April 2, 2016: 1:15 PM-3:15 PM</strong></p><p>Exhibit/Poster Hall (BCEC)</p><p></p><p>Poster Board SAT 154</p><p><em><strong>Maria Escobar Vasco</strong>[SUP]*[/SUP][SUP]1[/SUP], Devjit Tripathy[SUP]2[/SUP], Sheila Pinkson[SUP]3[/SUP] and Maureen Koops[SUP]4[/SUP]</em></p><p><em>[SUP]1[/SUP]University of Texas Health Science Center, San Antonio, TX, [SUP]2[/SUP]South Texas Veteran's Health Care System, San Antonio, TX, [SUP]3[/SUP]South Texas Veterans Health Care System, San Antonio, TX, [SUP]4[/SUP]University of Texas Health Science Center San Antonio, San Antonio, TX</em></p><p></p><p><strong>Introduction</strong>: Approximately 25-40% of men with type 2 diabetes have low testosterone concentrations. The data on risk of cardiovascular events in patients on testosterone replacement in Veterans is controversial. While one study showed reduced mortality and cardiovascular (CV) events, a recent study suggests that testosterone replacement therapy was associated with increased cardiovascular events. Since there are also isolated reports of increased thrombotic events with testosterone therapy, the aim of this study was to evaluate the incidence of venous thromboembolism (deep venous thrombosis (DVT) and pulmonary embolism (PE), and acute coronary syndromes (ACS) in patients with T2DM on testosterone replacement therapy.</p><p></p><p><strong>Methods</strong>: We reviewed the records of 140 veterans attending the VA Diabetes clinic (South Texas Veterans Heath Care System) who had total and free testosterone, LH, FSH, and prolactin levels measured. Data on incidence of DVT, PE and ACS was analyzed in all subjects who were followed for at least 6 months.</p><p></p><p><strong>Results:</strong> The mean age was 55 ± 0.5 years (range 23-82yrs), BMI was 33 ± 0.5 kg/m[SUP]2[/SUP] and mean HbA[SUB]1c[/SUB] was 8.2 ± 0.2%. Sixty nine percent (98/140) of men with T2DM were hypogonadal (T testosterone <300ng/dl). Sixty two individuals with T2DM had received testosterone therapy while 78 (37 hypogonad and 41 eugonad) were not on testosterone therapy. The mean duration of follow-up for patients on testosterone was 4.5± 1.5 years (range 6months- 16 years) and for those not on testosterone, the duration was 3.5 ± 0.5 years (range 6 months - 6 years). Of the 62 hypogonadal men on testosterone replacement therapy, 1 individual had a DVT diagnosed during therapy. Of note this subject also had a diagnosis of active malignancy at the time of the event. There were no reports of ACS, or PE in patients on testosterone replacement therapy. There were no CV events or DVT in hypogonadal or eugonadal subjects with T2DM who were not on testosterone therapy. </p><p> </p><p>C<strong>onclusion:</strong> Although the number of events was low, our study did not show increased CV events or VTE with testosterone replacement in hypogonadal men with T2DM followed for 3.5 years. Randomized controlled trials with longer follow-up are needed to examine the effect of testosterone replacement on CV events in T2DM.</p></blockquote><p></p>
[QUOTE="Nelson Vergel, post: 36835, member: 3"] [B]Effect of Testosterone Therapy on Cardiovascular and Thrombotic Events in Hypogonad Men with T2DM[/B] [B]Program:[/B] Abstracts - Orals, Poster Previews, and Posters [B]Session:[/B] SAT 134-160-Male Reproductive Endocrinology and Male Reproductive Tract (posters) Bench to Bedside [B]ENDO 2016 Meeting. Saturday, April 2, 2016: 1:15 PM-3:15 PM[/B] Exhibit/Poster Hall (BCEC) Poster Board SAT 154 [I][B]Maria Escobar Vasco[/B][SUP]*[/SUP][SUP]1[/SUP], Devjit Tripathy[SUP]2[/SUP], Sheila Pinkson[SUP]3[/SUP] and Maureen Koops[SUP]4[/SUP] [SUP]1[/SUP]University of Texas Health Science Center, San Antonio, TX, [SUP]2[/SUP]South Texas Veteran's Health Care System, San Antonio, TX, [SUP]3[/SUP]South Texas Veterans Health Care System, San Antonio, TX, [SUP]4[/SUP]University of Texas Health Science Center San Antonio, San Antonio, TX[/I] [B]Introduction[/B]: Approximately 25-40% of men with type 2 diabetes have low testosterone concentrations. The data on risk of cardiovascular events in patients on testosterone replacement in Veterans is controversial. While one study showed reduced mortality and cardiovascular (CV) events, a recent study suggests that testosterone replacement therapy was associated with increased cardiovascular events. Since there are also isolated reports of increased thrombotic events with testosterone therapy, the aim of this study was to evaluate the incidence of venous thromboembolism (deep venous thrombosis (DVT) and pulmonary embolism (PE), and acute coronary syndromes (ACS) in patients with T2DM on testosterone replacement therapy. [B]Methods[/B]: We reviewed the records of 140 veterans attending the VA Diabetes clinic (South Texas Veterans Heath Care System) who had total and free testosterone, LH, FSH, and prolactin levels measured. Data on incidence of DVT, PE and ACS was analyzed in all subjects who were followed for at least 6 months. [B]Results:[/B] The mean age was 55 ± 0.5 years (range 23-82yrs), BMI was 33 ± 0.5 kg/m[SUP]2[/SUP] and mean HbA[SUB]1c[/SUB] was 8.2 ± 0.2%. Sixty nine percent (98/140) of men with T2DM were hypogonadal (T testosterone <300ng/dl). Sixty two individuals with T2DM had received testosterone therapy while 78 (37 hypogonad and 41 eugonad) were not on testosterone therapy. The mean duration of follow-up for patients on testosterone was 4.5± 1.5 years (range 6months- 16 years) and for those not on testosterone, the duration was 3.5 ± 0.5 years (range 6 months - 6 years). Of the 62 hypogonadal men on testosterone replacement therapy, 1 individual had a DVT diagnosed during therapy. Of note this subject also had a diagnosis of active malignancy at the time of the event. There were no reports of ACS, or PE in patients on testosterone replacement therapy. There were no CV events or DVT in hypogonadal or eugonadal subjects with T2DM who were not on testosterone therapy. C[B]onclusion:[/B] Although the number of events was low, our study did not show increased CV events or VTE with testosterone replacement in hypogonadal men with T2DM followed for 3.5 years. Randomized controlled trials with longer follow-up are needed to examine the effect of testosterone replacement on CV events in T2DM. [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone Side Effect Management
No Heart or Clotting Issues in Diabetic Men Using Testosterone after 3.5 years
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top